Livongo (NASDAQ:LVGO) Reports Fourth Quarter and Full Year Financial Results
Q4 Results
Revenue: $50.4 million (up 137% year-over-year) vs analyst expectations of $48.9 million
Adj EPS: -$0.06 vs analyst expectations of -$0.05
Full Year 2019 in Review
Revenue: Total revenue for the year was $170.2 million, up 149% year-over-year, and exceeding guidance range of $168.5 million to $169.0 million.
Livongo for Diabetes Members: 222,700 Members as of December 31, 2019, up 96% year-over-year.
Livongo Clients: 804 Clients as of December 31, 2019, up 95% year-over-year.
Customers: 30% of Fortune 500 companies vs 20% last year
Estimated Value of Agreements (EVA): $76.7 million, up from $56.1 million in the fourth quarter of 2018. It consists of the estimated value of agreements signed in the quarter with new Clients or expansions entered into with existing Clients.
Q1 Guidance
Revenue: $60 million - $62 million vs analyst expectations of $57 million
Full Year 2020 Guidance
Revenue: $280 million-$290 million (revenue to grow between 65% and 71%) vs analyst expectations of $277.5 million
Did You Know... LVGO is on our list, and there are 19 more...
Each company in our 'Top Picks’ has been selected as a future crown jewel of technology. Market correction or not, recession or not, the growth in these areas is a near certainty.
The precious few thematic top picks, research dossiers, and alerts are available for a limited time at a 30% discount.